About Cytochrome P450 4X1
Cytochrome P450 4X1 (CYP4X1) is a protein
from Homo sapiens identified by UniProt accession
Q8N118, 509 residues long.
MolForge cross-references it against 0 known binders and
47 disease associations.
Target properties
| Protein name | Cytochrome P450 4X1 |
| UniProt accession | Q8N118 |
| Gene | CYP4X1 |
| Organism | Homo sapiens |
| Length | 509 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (47)
Diseases linked to this target (Open Targets).
- astrocytoma · score 0.04
- atypical teratoid rhabdoid tumor · score 0.04
- central nervous system cancer · score 0.03
- ependymoma · score 0.03
- glioblastoma multiforme · score 0.03
- Obesity · score 0.03
- obesity · score 0.03
- medulloblastoma · score 0.02
- oligodendroglioma · score 0.02
- large cell medulloblastoma · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8N118-F1 | alphafold | PREDICTED | 89.07 | — |
Amino-acid sequence (509 residues)
MEFSWLETRW ARPFYLAFVF CLALGLLQAI KLYLRRQRLL RDLRPFPAPP THWFLGHQKF IQDDNMEKLE EIIEKYPRAF PFWIGPFQAF FCIYDPDYAK TLLSRTDPKS QYLQKFSPPL LGKGLAALDG PKWFQHRRLL TPGFHFNILK AYIEVMAHSV KMMLDKWEKI CSTQDTSVEV YEHINSMSLD IIMKCAFSKE TNCQTNSTHD PYAKAIFELS KIIFHRLYSL LYHSDIIFKL SPQGYRFQKL SRVLNQYTDT IIQERKKSLQ AGVKQDNTPK RKYQDFLDIV LSAKDESGSS FSDIDVHSEV STFLLAGHDT LAASISWILY CLALNPEHQE RCREEVRGIL GDGSSITWDQ LGEMSYTTMC IKETCRLIPA VPSISRDLSK PLTFPDGCTL PAGITVVLSI WGLHHNPAVW KNPKVFDPLR FSQENSDQRH PYAYLPFSAG SRNCIGQEFA MIELKVTIAL ILLHFRVTPD PTRPLTFPNH FILKPKNGMY LHLKKLSEC
Explore Cytochrome P450 4X1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets